BioNTech SE

BRSE:22UA Stock Report

Market Cap: CHF 18.9b

BioNTech Valuation

Is 22UA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 22UA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate 22UA's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate 22UA's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 22UA?

Key metric: As 22UA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 22UA. This is calculated by dividing 22UA's market cap by their current revenue.
What is 22UA's PS Ratio?
PS Ratio7.2x
Sales€2.87b
Market Cap€20.54b

Price to Sales Ratio vs Peers

How does 22UA's PS Ratio compare to its peers?

The above table shows the PS ratio for 22UA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.5x
IDIA Idorsia
4x15.86%CHF 882.8m
BSLN Basilea Pharmaceutica
2.9x11.65%CHF 674.8m
KURN Kuros Biosciences
8.6x23.92%CHF 984.1m
MRNA Moderna
10.3x23.91%US$20.2b
22UA BioNTech
7.2x-1.66%CHF 24.2b

Price-To-Sales vs Peers: 22UA is expensive based on its Price-To-Sales Ratio (7.2x) compared to the peer average (6.5x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 22UA's PS Ratio compare vs other companies in the European Biotechs Industry?

59 CompaniesPrice / SalesEstimated GrowthMarket Cap
22UA 7.2xIndustry Avg. 7.7xNo. of Companies59PS01224364860+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 22UA is good value based on its Price-To-Sales Ratio (7.2x) compared to the European Biotechs industry average (7.7x).

Price to Sales Ratio vs Fair Ratio

What is 22UA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

22UA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.2x
Fair PS Ratio5.4x

Price-To-Sales vs Fair Ratio: 22UA is expensive based on its Price-To-Sales Ratio (7.2x) compared to the estimated Fair Price-To-Sales Ratio (5.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 22UA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 77.44
CHF 104.05
+34.36%
18.14%CHF 136.66CHF 60.53n/a18
Apr ’27CHF 71.48
CHF 105.06
+46.98%
17.06%CHF 137.01CHF 60.69n/a18
Mar ’27CHF 85.23
CHF 107.45
+26.08%
12.09%CHF 135.22CHF 79.18n/a19
Feb ’27CHF 89.12
CHF 108.57
+21.82%
12.04%CHF 136.40CHF 79.87n/a19
Jan ’27CHF 75.20
CHF 110.15
+46.47%
12.73%CHF 138.86CHF 81.31n/a19
Dec ’26CHF 80.35
CHF 110.32
+37.30%
12.68%CHF 139.02CHF 81.40n/a19
Nov ’26CHF 83.96
CHF 107.40
+27.91%
12.54%CHF 137.20CHF 78.83n/a20
Oct ’26n/a
CHF 108.57
0%
12.51%CHF 138.13CHF 79.47n/a20
Sep ’26n/a
CHF 110.03
0%
10.95%CHF 138.24CHF 89.82n/a20
Aug ’26CHF 90.32
CHF 109.72
+21.48%
12.69%CHF 138.90CHF 89.42n/a20
Jul ’26CHF 85.10
CHF 109.34
+28.49%
15.32%CHF 139.88CHF 67.79n/a21
Jun ’26CHF 83.11
CHF 108.26
+30.26%
15.16%CHF 140.77CHF 67.64n/a22
May ’26CHF 85.11
CHF 115.47
+35.68%
12.86%CHF 147.80CHF 92.37n/a20
Apr ’26CHF 80.54
CHF 121.19
+50.48%
11.66%CHF 150.28CHF 96.84CHF 71.4821
Mar ’26CHF 95.99
CHF 125.84
+31.10%
11.81%CHF 155.94CHF 106.99CHF 85.2320
Feb ’26CHF 110.18
CHF 126.49
+14.80%
12.13%CHF 157.87CHF 107.97CHF 89.1220
Jan ’26CHF 102.53
CHF 122.15
+19.13%
10.85%CHF 152.44CHF 107.49CHF 75.2019
Dec ’25CHF 107.28
CHF 120.69
+12.50%
9.64%CHF 152.54CHF 107.66CHF 80.3518
Nov ’25n/a
CHF 112.35
0%
17.13%CHF 148.58CHF 77.67CHF 83.9618
Oct ’25CHF 101.13
CHF 104.83
+3.66%
19.60%CHF 144.68CHF 71.91n/a18
Sep ’25CHF 74.97
CHF 93.38
+24.55%
20.43%CHF 146.44CHF 72.79n/a18
Aug ’25CHF 76.19
CHF 97.51
+27.98%
20.32%CHF 149.47CHF 78.74CHF 90.3218
Jul ’25CHF 73.23
CHF 99.23
+35.49%
20.23%CHF 152.93CHF 80.05CHF 85.1018
Jun ’25CHF 90.34
CHF 100.88
+11.66%
20.40%CHF 155.28CHF 81.46CHF 83.1118
May ’25CHF 80.78
CHF 104.37
+29.20%
20.66%CHF 154.20CHF 81.51CHF 85.1118
Apr ’25n/a
CHF 105.78
0%
23.56%CHF 168.60CHF 81.03CHF 80.5418
CHF 106.32
Fair Value
27.2% undervalued intrinsic discount
18
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/13 05:37
End of Day Share Price 2026/04/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioNTech SE is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Harry GillisBerenberg
Zhiqiang ShuBerenberg